A new pharma-funded study shows that lower co-pays equal higher adherence to drug regimens. The implications is that by spending some money up front on drugs for chronic diseases, companies might save in the long run on complications. Report
A new pharma-funded study shows that lower co-pays equal higher adherence to drug regimens. The implications is that by spending some money up front on drugs for chronic diseases, companies might save in the long run on complications. Report